336 related articles for article (PubMed ID: 23333581)
1. Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function.
Imig JD
Prostaglandins Other Lipid Mediat; 2013; 104-105():2-7. PubMed ID: 23333581
[TBL] [Abstract][Full Text] [Related]
2. Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology.
Sacerdoti D; Gatta A; McGiff JC
Prostaglandins Other Lipid Mediat; 2003 Oct; 72(1-2):51-71. PubMed ID: 14626496
[TBL] [Abstract][Full Text] [Related]
3. Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function.
Imig JD
Adv Pharmacol; 2016; 77():105-41. PubMed ID: 27451096
[TBL] [Abstract][Full Text] [Related]
4. P-450 metabolites of arachidonic acid in the control of cardiovascular function.
Roman RJ
Physiol Rev; 2002 Jan; 82(1):131-85. PubMed ID: 11773611
[TBL] [Abstract][Full Text] [Related]
5. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation.
Oltman CL; Weintraub NL; VanRollins M; Dellsperger KC
Circ Res; 1998 Nov; 83(9):932-9. PubMed ID: 9797342
[TBL] [Abstract][Full Text] [Related]
6. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease.
Minuz P; Jiang H; Fava C; Turolo L; Tacconelli S; Ricci M; Patrignani P; Morganti A; Lechi A; McGiff JC
Hypertension; 2008 May; 51(5):1379-85. PubMed ID: 18378855
[TBL] [Abstract][Full Text] [Related]
7. Role of cytochrome P450 metabolites of arachidonic acid in regulation of corporal smooth muscle tone in diabetic and older rats.
Yousif MH; Benter IF
Vascul Pharmacol; 2007; 47(5-6):281-7. PubMed ID: 17855173
[TBL] [Abstract][Full Text] [Related]
8. Kidney CYP450 enzymes: biological actions beyond drug metabolism.
Zhao X; Imig JD
Curr Drug Metab; 2003 Feb; 4(1):73-84. PubMed ID: 12570747
[TBL] [Abstract][Full Text] [Related]
9. Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids.
Roman RJ; Maier KG; Sun CW; Harder DR; Alonso-Galicia M
Clin Exp Pharmacol Physiol; 2000 Nov; 27(11):855-65. PubMed ID: 11071299
[TBL] [Abstract][Full Text] [Related]
10. Epoxyeicosatrienoic acids and endothelium-dependent responses.
Campbell WB; Fleming I
Pflugers Arch; 2010 May; 459(6):881-95. PubMed ID: 20224870
[TBL] [Abstract][Full Text] [Related]
11. Increases in levels of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids (EETs and DHETs) in liver and heart in vivo by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and in hepatic EET:DHET ratios by cotreatment with TCDD and the soluble epoxide hydrolase inhibitor AUDA.
Diani-Moore S; Ma Y; Gross SS; Rifkind AB
Drug Metab Dispos; 2014 Feb; 42(2):294-300. PubMed ID: 24311719
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 metabolites of arachidonic acid in the control of renal function.
Maier KG; Roman RJ
Curr Opin Nephrol Hypertens; 2001 Jan; 10(1):81-7. PubMed ID: 11195057
[TBL] [Abstract][Full Text] [Related]
13. Age-related changes in renal cytochrome P-450 arachidonic acid metabolism in spontaneously hypertensive rats.
Omata K; Abraham NG; Escalante B; Schwartzman ML
Am J Physiol; 1992 Jan; 262(1 Pt 2):F8-16. PubMed ID: 1733300
[TBL] [Abstract][Full Text] [Related]
14. Vascular pharmacology of epoxyeicosatrienoic acids.
Pfister SL; Gauthier KM; Campbell WB
Adv Pharmacol; 2010; 60():27-59. PubMed ID: 21081214
[TBL] [Abstract][Full Text] [Related]
15. Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury.
Nithipatikom K; Moore JM; Isbell MA; Falck JR; Gross GJ
Am J Physiol Heart Circ Physiol; 2006 Aug; 291(2):H537-42. PubMed ID: 16473964
[TBL] [Abstract][Full Text] [Related]
16. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function.
Spector AA; Fang X; Snyder GD; Weintraub NL
Prog Lipid Res; 2004 Jan; 43(1):55-90. PubMed ID: 14636671
[TBL] [Abstract][Full Text] [Related]
17. Differential contribution of renal cytochrome P450 enzymes to kidney endothelial dysfunction and vascular oxidative stress in obesity.
Muñoz M; López-Oliva E; Pinilla E; Rodríguez C; Martínez MP; Contreras C; Gómez A; Benedito S; Sáenz-Medina J; Rivera L; Prieto D
Biochem Pharmacol; 2022 Jan; 195():114850. PubMed ID: 34822809
[TBL] [Abstract][Full Text] [Related]
18. The factor in EDHF: Cytochrome P450 derived lipid mediators and vascular signaling.
Fleming I
Vascul Pharmacol; 2016 Nov; 86():31-40. PubMed ID: 26975734
[TBL] [Abstract][Full Text] [Related]
19. EET homologs potently dilate coronary microvessels and activate BK(Ca) channels.
Zhang Y; Oltman CL; Lu T; Lee HC; Dellsperger KC; VanRollins M
Am J Physiol Heart Circ Physiol; 2001 Jun; 280(6):H2430-40. PubMed ID: 11356595
[TBL] [Abstract][Full Text] [Related]
20. 5,6-δ-DHTL, a stable metabolite of arachidonic acid, is a potential EDHF that mediates microvascular dilation.
Levi-Rosenzvig R; Beyer AM; Hockenberry J; Ben-Shushan RS; Chuyun D; Atiya S; Tamir S; Gutterman DD; Szuchman-Sapir A
Free Radic Biol Med; 2017 Feb; 103():87-94. PubMed ID: 28007573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
